~~<i id='36646276A4'><strike id='36646276A4'><tt id='36646276A4'><pre id='36646276A4'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

comprehensive

author：explore 2025-09-27 12:48:37 - browse：5529

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Diversity in medical illustrations gets boost from Chidiebere Ibe

leisure time

Wikipedia

knowledge

focus

knowledge

focus

AdobeThefederalgovernment’splantoboostitsoversightoftheuseofartificialintelligencetoolsinhealthcared

WSS

Secretariat’s lessons for human medicine

Abridge raises $150m as clinical notes automation market heats up

Medicare Advantage enrollment hits roughly 33.4 million

In science, is the line between industry and academia shifting?

New study raises questions about niacin and heart health

Drug firms test therapies to halt Alzheimer’s before symptoms arise

hotspot

comprehensive

leisure time

How to save PrEP access — and even expand it

Measles policy set amid Florida outbreak alarms vaccine proponents

Hepatitis C has a cure — but many Americans still lack access to it

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

As pharma fights Medicare drug negotiation, hospitals, docs silent

DIEP, the 'gold standard' of breast reconstruction, is under threat

Appeals court upholds limits to abortion pill

Hepatitis C has a cure — but many Americans still lack access to it

2024 GOP presidential candidates spar over abortion in debate

Wikipedia

A new drug could help frostbite victims avoid its ravages

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Diversity in medical illustrations gets boost from Chidiebere Ibe

Departing Stanford president retracts two papers

knowledge

focus

knowledge

focus